Agenus | AGEN - Current Liabilities


Agenus reported $231.82M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AbbVie USD 41.64B 458M Jun/2026
Agenus USD 231.82M 17.42M Jun/2026
Amgen USD 25.5B 547M Jun/2026
AstraZeneca USD 31.55B 1.02B Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Celldex Therapeutics USD 61.32M 9.85M Jun/2026
CSL USD 4.61B 207M Dec/2025
Eli Lilly USD 47.74B 11.11B Jun/2026
Gilead Sciences USD 11.02B 1.54B Jun/2026
GlaxoSmithKline GBP 21.53B 895M Jun/2026
Glaxosmithkline GBP 22.43B 6.39B Mar/2026
Incyte USD 1.31B 177.55M Jun/2026
Intrexon USD 23.02M 38K Jun/2024
J&J USD 54.9B 2.82B Jun/2026
Jiangsu Hengrui CNY 5.64B 732.51M Mar/2026
Karyopharm Therapeutics USD 117.3M 25.24M Mar/2026
MacroGenics USD 108.82M 12.88M Jun/2026
Merck EUR 8.12B 1.22B Jun/2026
Merck USD 27.73B 786M Jun/2026
Northwest Biotherapeutics USD 82.97M 4.93M Mar/2026
Novartis USD 31.75B 374M Jun/2026
Novavax USD 330.57M 11.89M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Regeneron Pharmaceuticals USD 5.53B 422.9M Jun/2026
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Veracyte USD 62.74M 6.62M Jun/2026